Sagimet Biosciences
SGMT
SGMT
82 hedge funds and large institutions have $71.6M invested in Sagimet Biosciences in 2024 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 22 increasing their positions, 21 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
36.89% less ownership
Funds ownership: 105.75% → 68.86% (-37%)
42% less capital invested
Capital invested by funds: $122M → $71.6M (-$50.8M)
98% less call options, than puts
Call options by funds: $3K | Put options by funds: $134K
Holders
82
Holding in Top 10
3
Calls
$3K
Puts
$134K
Top Buyers
| 1 | +$3.98M | |
| 2 | +$882K | |
| 3 | +$813K | |
| 4 |
Goldman Sachs
New York
|
+$795K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$616K |
Top Sellers
| 1 | -$3.84M | |
| 2 | -$3.69M | |
| 3 | -$1.71M | |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1.63M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.03M |